Drugs / CTP0302-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06287606 | Aug 2023 → Jan 2024 | — | Taejoon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTP0302-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06287606 ↗ |